ClinicalTrials.gg
Sign In
Active, not recruitingNCT07692581Updated Jul 9, 2026

A Clinical Trial to Evaluate the Effects of Larineco Remineralizing Gum on Oral Health, Breath Freshness, Tooth Sensitivity, and Gum Comfort

An interventional study of Larineco Remineralizing Gum in Bad Breath and Tooth Sensitivity, sponsored by Larine C Corporation. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Larine C Corporation · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as active, not recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a single-group, open-label, decentralized (virtual) clinical trial evaluating the effects of Larineco Remineralizing Gum on self-reported oral health outcomes in 40 generally healthy adults aged 18-57 years who experience bad breath, sensitive teeth, or gum discomfort. Participants will use the product once daily for 30 consecutive days and complete questionnaires at Baseline, Day 10, Day 20, and Day 30.

02

Conditions studied

  • Bad Breath
  • Tooth Sensitivity

Keywords

  • Gum Discomfort
03

In context

Halitosis

93 studies on the registry are indexed under Halitosis; 17 are open to participants now.

This study's planned enrollment of 40 is below the median of 45 across 79 interventional studies indexed under Halitosis.

Browse Halitosis studies →

Lead sponsor

This is the only study on the registry with Larine C Corporation as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be male or female
  • Be adults aged 18-57 years
  • Self-reports experiencing at least one of the following oral concerns: bad breath, tooth sensitivity, or gum discomfort Generally healthy
  • Able to safely chew gum-style products
  • Willing to use the study product as directed, using one piece of gum per day, after the second meal of the day, and chewing thoroughly for 15 minutes before discarding, for the trial duration
  • Willing to maintain current oral hygiene habits (e.g., brushing frequency, flossing routine, toothpaste product) Resides in the United States Anyone who is willing to maintain their current diet, sleep pattern, and activity levels for the duration of the trial Has reliable access to an internet-enabled device to complete remote study assessments
  • Anyone willing to follow the study protocol
  • Willing to store the study product as directed and keep it away from children and pets

Exclusion criteria

Exclusion Criteria:

  • Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and mental health disorders
  • Known allergy or to any ingredient in the study product
  • Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period)
  • Severe or unmanaged dental or oral conditions (e.g., active oral infection, extensive untreated cavities, severe periodontitis, oral ulcers, or recent oral surgery within the past 30 days)
  • Loose or temporary dental work (e.g., temporary crowns, loose veneers, recently placed braces) that may be affected by chewing gummies
  • Diagnosed temporomandibular joint (TMJ) disorder or significant jaw pain that would make chewing uncomfortable
  • Known dry mouth/xerostomia or significant mouth sensitivity that may interfere with product tolerance or assessment
  • History of significant gastrointestinal sensitivity or digestive conditions that may be worsened by sugar alcohols, sweeteners, or functional ingredients
  • Recent dental procedure (within the past 14 days) or planned dental work during the study period that may interfere with assessments
  • Currently wearing fixed orthodontic appliances (e.g., traditional braces) that would significantly affect product use or assessments
  • Currently partaking in another research study or will be partaking in any other research study for the next 30 days, and at any point during this study's duration
  • Anyone who is undergoing treatment for cancer, or has had a serious illness requiring hospitalization in the last three months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Larineco Remineralizing Gum

    Dietary Supplement: Larineco Remineralizing Gum

Interventions

  • Dietary supplementLarineco Remineralizing Gum

    All enrolled participants receive Larineco Remineralizing Gum, a commercially available chewing gum product. Participants chew one piece of gum per day, after the second meal of the day, slowly and thoroughly for 15 minutes before discarding, for 30 consecutive days.

06

What researchers measure

Primary outcomes

  1. Oral Health

    Change in self-reported oral health using questionnaires assessing breath freshness, tooth sensitivity, and gum comfort

    Time frame: Baseline, day 10, day 20, day 30

Secondary outcomes

  1. Tooth surface smoothness

    Change in self-reported tooth surface smoothness via self-report questionnaire on the Citruslabs study platform.

    Time frame: Baseline, day 10, day 20, day 30

  2. Mouth cleanliness

    Change in self reported mouth cleanliness via self-report questionnaire on the Citruslabs study platform.

    Time frame: Baseline, Day 10, Day 20, and Day 30

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Aug 2026, 1 month after the start.

Of 43 interventional studies with no phase under Halitosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 18. This study's planned 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2026
First posted
Jul 9, 2026
StartActual
Jul 2, 2026
Primary completionEst.
Aug 2026
CompletionEst.
Aug 2026
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07692581
Lead sponsor
Larine C Corporation
Collaborators
Citruslabs
Responsible party
Sponsor
First posted
Jul 9, 2026
Start date
Jul 2, 2026
Primary completion
Aug 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
Jul 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Halitosis →

Start the discussion